News
Second-quarter adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, beating expectations.
Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...
GlobalData on MSN2d
Pfizer shares rise 3% after upping profit forecast for 2025Pfizer bucked the trend of a tepid big pharma Q2 window, raising its full-year profit forecast on the back of strong sales ...
Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
According to the FDA, Comirnaty has the same formulation as the Pfizer COVID-19 vaccine that was previously authorized for emergency use (EUA) in the United States. It will continue to be ...
Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback